ME02865B - C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae) - Google Patents
C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)Info
- Publication number
- ME02865B ME02865B MEP-2017-182A MEP2017182A ME02865B ME 02865 B ME02865 B ME 02865B ME P2017182 A MEP2017182 A ME P2017182A ME 02865 B ME02865 B ME 02865B
- Authority
- ME
- Montenegro
- Prior art keywords
- composition
- esterase inhibitor
- use according
- units
- hae
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791399P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030309 WO2014145519A2 (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficency |
| EP14762343.3A EP2968434B1 (en) | 2013-03-15 | 2014-03-17 | C1-inh compositions for use in the prevention and treatment of hereditary angioedema (hae). |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02865B true ME02865B (me) | 2018-04-20 |
Family
ID=51538486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-182A ME02865B (me) | 2013-03-15 | 2014-03-17 | C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae) |
| MEP-2019-45A ME03326B (me) | 2013-03-15 | 2014-03-17 | C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2019-45A ME03326B (me) | 2013-03-15 | 2014-03-17 | C1-inh kompozicije i postupci za prevenciju i liječenje poremećaja koji su povezani sa deficijencijom inhibitora c1 esteraze |
Country Status (30)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3290046T (lt) | 2013-03-15 | 2019-03-12 | Shire Viropharma Incorporated | C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai |
| HRP20190184T1 (hr) | 2013-11-22 | 2019-03-22 | Shire Viropharma Incorporated | Postupci liječenja odbacivanja uzrokovanog protutijelima kod pacijenata s presađenim organom inhibitorom esteraze c1 |
| SG11201706019XA (en) * | 2015-02-20 | 2017-09-28 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
| HK1250623A1 (zh) * | 2015-05-28 | 2019-01-11 | Cornell University | 腺相关病毒介导的c1ei递送作为用於血管性水肿的疗法 |
| CN108463243B (zh) * | 2015-11-19 | 2022-06-14 | 夏尔人类遗传性治疗公司 | 重组人c1酯酶抑制剂及其用途 |
| AU2017305856B2 (en) * | 2016-08-05 | 2024-09-12 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
| JP2019534240A (ja) * | 2016-08-23 | 2019-11-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Ｃ１エステラーゼ阻害剤欠乏に関連する遺伝性血管浮腫の急性発作を予防する方法 |
| AU2018269656B2 (en) * | 2017-05-16 | 2024-07-11 | Octapharma Ag | C1-esterase inhibitor preparation |
| MX2020008969A (es) | 2018-02-28 | 2021-02-16 | Pharming Intellectual Property B V | Tratamiento y prevencion de preeclampsia. |
| WO2019166572A1 (en) | 2018-02-28 | 2019-09-06 | Pharming Intellectual Property B.V. | Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor |
| KR20250096878A (ko) | 2018-06-22 | 2025-06-27 | 가부시키가이샤 준텐 바이오 | 복합 상태를 갖는 세포 혼합물을 이용한, 면역 관용을 유도하는 항체 및 유도된 림프구, 또는 유도된 림프구를 이용하는 세포 치료제 및 치료법 |
| US12139537B2 (en) | 2018-06-22 | 2024-11-12 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
| AU2019288684A1 (en) | 2018-06-22 | 2021-01-21 | Junten Bio Co., Ltd. | Composition for eliciting infectious immunological tolerance |
| EP4079325A1 (en) * | 2019-12-16 | 2022-10-26 | Nipro Corporation | Aggregation inhibitory agent and medical composition and medical device including same |
| EP3895726A1 (en) | 2020-04-17 | 2021-10-20 | Pharming Intellectual Property BV | Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress |
| US20240342258A1 (en) | 2021-07-09 | 2024-10-17 | Pharming Intellectual Property B.V. | Using c1 esterase inhibitor to treat viral infection-related symptoms |
| KR20230046146A (ko) | 2021-09-29 | 2023-04-05 | 주식회사 엘지에너지솔루션 | 배터리 제어 시스템 및 방법 |
| WO2025090843A1 (en) * | 2023-10-27 | 2025-05-01 | Kansas State University Research Foundation | Small-molecule inhibitors of c1s protease and classical complement pathway |
| CN119823254B (zh) * | 2025-03-14 | 2025-06-03 | 深圳市卫光生物制品股份有限公司 | 一种c1酯酶抑制剂重组变体及其制备方法和应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304482A (en) | 1989-03-06 | 1994-04-19 | The Board Of Regents Of The University Of Texas System | Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors |
| WO1992022320A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | C1 inhibitor variants and treating inflammatory response with c1 inhibitor |
| DE69429816T2 (de) | 1993-09-01 | 2002-09-19 | Stichting Sanquin Bloedvoorziening, Amsterdam | C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt |
| WO1997022347A1 (en) | 1995-12-18 | 1997-06-26 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
| AT409336B (de) | 1999-12-22 | 2002-07-25 | Baxter Ag | Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung |
| US7067713B2 (en) * | 2000-01-31 | 2006-06-27 | Pharming Intellectual Property B.V. | C1 Inhibitor produced in the milk of transgenic non-human mammals |
| EP1252184B1 (en) | 2000-01-31 | 2008-01-02 | Pharming Intellectual Property B.V. | Human c1 inhibitor produced in the milk of transgenic mammals |
| ATE442862T2 (de) | 2000-10-12 | 2009-10-15 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| DE10112617A1 (de) | 2001-03-14 | 2002-10-02 | Aventis Behring Gmbh | Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren |
| WO2004034971A2 (en) | 2002-09-25 | 2004-04-29 | The Center For Blood Research, Inc. | Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| USRE43691E1 (en) | 2003-05-16 | 2012-09-25 | Pharming Intellectual Property B.V. | C1 inhibitor with short half-life transient treatment |
| US20060233776A1 (en) | 2003-08-19 | 2006-10-19 | Norbert Heimburger | C1-inh as a drug for treating viruses pathogenic to humans |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| EP1598428A1 (en) | 2004-05-18 | 2005-11-23 | Georg Dewald | Methods and kits to detect Hereditary angioedema type III |
| EP2529746A1 (en) | 2005-06-06 | 2012-12-05 | Girish J. Kotwal | Methods for treatment or prophylaxis of reperfusion injury |
| EP2433642B1 (en) | 2005-10-21 | 2016-12-07 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
| ES2654816T3 (es) * | 2005-12-21 | 2018-02-15 | Pharming Intellectual Property B.V. | Uso del inhibidor C1 para la prevención de lesión de reperfusión de isquemia |
| KR101508668B1 (ko) | 2005-12-21 | 2015-04-06 | 파밍 인텔렉츄얼 프라퍼티 비.브이. | 허혈-재관류 손상의 예방을 위한 ｃ１ 억제제의 용도 |
| US7837992B2 (en) | 2006-06-22 | 2010-11-23 | Beth Israel Deaconess Medical Center | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| CN101969971A (zh) | 2007-11-30 | 2011-02-09 | 雅培制药有限公司 | 蛋白制剂及其制备方法 |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20100143325A1 (en) | 2008-12-09 | 2010-06-10 | Vascular Laboratory, Inc. | Composition And Methods Involving Thrombolytic Agents |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| SI2488203T1 (sl) | 2009-10-16 | 2017-07-31 | Omeros Corporation | Metode za zdravljenje diseminirane intravaskularne koagulacije z inhibiranjem aktivacije masp-2 odvisnega komplementa |
| EP3815708A1 (en) | 2010-03-05 | 2021-05-05 | Omeros Corporation | Chimeric inhibitor molecules of complement activation |
| US20130085111A1 (en) * | 2010-03-18 | 2013-04-04 | Thrombolytic Science, Llc | Production of human c1 inhibitor in human cells |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| JP6190368B2 (ja) | 2011-09-24 | 2017-08-30 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 免疫グロブリンおよびｃ１−阻害剤を用いる組合せ療法 |
| DK2793935T3 (en) | 2011-12-22 | 2016-09-05 | Csl Behring Gmbh | Use of C1 inhibitor in the treatment of secondary edema in the central nervous system. |
| WO2013138730A1 (en) | 2012-03-16 | 2013-09-19 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of c1-inhibitors |
| US20160033511A1 (en) | 2013-03-13 | 2016-02-04 | Creatics Llc | Methods and compositions for detecting pancreatic cancer |
| LT3290046T (lt) * | 2013-03-15 | 2019-03-12 | Shire Viropharma Incorporated | C1-inh kompozicijos ir sutrikimų, susijusių su c1 esterazės inhibitoriaus nepakankamumu, prevencijos bei gydymo būdai |
| JP6889626B2 (ja) * | 2017-06-29 | 2021-06-18 | トキコシステムソリューションズ株式会社 | 燃料供給システム |
| JP6935245B2 (ja) * | 2017-06-29 | 2021-09-15 | 大和ハウス工業株式会社 | 収容ラック |
-
2014
- 2014-03-17 LT LTEP17177676.8T patent/LT3290046T/lt unknown
- 2014-03-17 HU HUE17177676A patent/HUE041837T2/hu unknown
- 2014-03-17 ME MEP-2017-182A patent/ME02865B/me unknown
- 2014-03-17 RS RS20190198A patent/RS58351B1/sr unknown
- 2014-03-17 KR KR1020227016244A patent/KR102579789B1/ko active Active
- 2014-03-17 TR TR2019/00319T patent/TR201900319T4/tr unknown
- 2014-03-17 PL PL14762343T patent/PL2968434T3/pl unknown
- 2014-03-17 ME MEP-2019-45A patent/ME03326B/me unknown
- 2014-03-17 DE DE202014011208.8U patent/DE202014011208U1/de not_active Expired - Lifetime
- 2014-03-17 CN CN201480014712.7A patent/CN105517559A/zh active Pending
- 2014-03-17 JP JP2016503371A patent/JP6184581B2/ja active Active
- 2014-03-17 SG SG11201507616VA patent/SG11201507616VA/en unknown
- 2014-03-17 SM SM20170415T patent/SMT201700415T1/it unknown
- 2014-03-17 MX MX2015011281A patent/MX373965B/es active IP Right Grant
- 2014-03-17 EA EA201591278A patent/EA201591278A1/ru unknown
- 2014-03-17 PT PT147623433T patent/PT2968434T/pt unknown
- 2014-03-17 SI SI201430368T patent/SI2968434T1/sl unknown
- 2014-03-17 KR KR1020217004777A patent/KR20210021146A/ko not_active Ceased
- 2014-03-17 MX MX2020004724A patent/MX389449B/es unknown
- 2014-03-17 PL PL17177676T patent/PL3290046T3/pl unknown
- 2014-03-17 DK DK17177676.8T patent/DK3290046T3/en active
- 2014-03-17 WO PCT/US2014/030309 patent/WO2014145519A2/en not_active Ceased
- 2014-03-17 ES ES14762343.3T patent/ES2639833T3/es active Active
- 2014-03-17 HU HUE14762343A patent/HUE036224T2/hu unknown
- 2014-03-17 RS RS20170802A patent/RS56285B1/sr unknown
- 2014-03-17 SG SG10201707598QA patent/SG10201707598QA/en unknown
- 2014-03-17 KR KR1020157022897A patent/KR20150135242A/ko not_active Ceased
- 2014-03-17 PT PT17177676T patent/PT3290046T/pt unknown
- 2014-03-17 KR KR1020217033628A patent/KR102430453B1/ko active Active
- 2014-03-17 BR BR112015023207A patent/BR112015023207A8/pt not_active Application Discontinuation
- 2014-03-17 CN CN202010362851.6A patent/CN111529708A/zh active Pending
- 2014-03-17 EP EP18206413.9A patent/EP3508213A1/en not_active Withdrawn
- 2014-03-17 LT LTEP14762343.3T patent/LT2968434T/lt unknown
- 2014-03-17 SM SM20190141T patent/SMT201900141T1/it unknown
- 2014-03-17 HR HRP20171269TT patent/HRP20171269T1/hr unknown
- 2014-03-17 CA CA3054718A patent/CA3054718A1/en not_active Abandoned
- 2014-03-17 GB GB1519921.9A patent/GB2530921B/en active Active
- 2014-03-17 SI SI201431032T patent/SI3290046T1/sl unknown
- 2014-03-17 DK DK14762343.3T patent/DK2968434T3/en active
- 2014-03-17 AU AU2014232912A patent/AU2014232912A1/en not_active Abandoned
- 2014-03-17 ES ES17177676T patent/ES2713004T3/es active Active
- 2014-03-17 EP EP17177676.8A patent/EP3290046B1/en active Active
- 2014-03-17 EP EP14762343.3A patent/EP2968434B1/en not_active Revoked
- 2014-03-17 CA CA2904543A patent/CA2904543C/en active Active
-
2015
- 2015-08-28 MX MX2021011946A patent/MX2021011946A/es unknown
- 2015-09-10 IL IL241549A patent/IL241549B/en active IP Right Grant
- 2015-09-15 US US14/855,168 patent/US9616111B2/en active Active
- 2015-10-13 ZA ZA2015/07604A patent/ZA201507604B/en unknown
-
2017
- 2017-01-20 US US15/411,744 patent/US20170224788A1/en not_active Abandoned
- 2017-03-16 JP JP2017051361A patent/JP6422520B2/ja active Active
- 2017-09-12 CY CY20171100961T patent/CY1119419T1/el unknown
- 2017-10-12 ZA ZA2017/06929A patent/ZA201706929B/en unknown
- 2017-12-11 US US15/837,938 patent/US10130690B2/en active Active
- 2017-12-11 US US15/837,677 patent/US10080788B2/en active Active
- 2017-12-11 US US15/837,693 patent/US10105423B2/en active Active
- 2017-12-11 US US15/837,969 patent/US10201595B2/en active Active
-
2018
- 2018-04-06 JP JP2018073690A patent/JP6473535B2/ja active Active
- 2018-04-06 JP JP2018073689A patent/JP6473534B2/ja active Active
- 2018-04-06 JP JP2018073691A patent/JP6473536B2/ja active Active
- 2018-08-02 US US16/053,457 patent/US11534482B2/en active Active
- 2018-08-10 HK HK18110262.0A patent/HK1250912B/en unknown
- 2018-09-05 US US16/122,015 patent/US20190160158A1/en not_active Abandoned
- 2018-09-17 AU AU2018229558A patent/AU2018229558B2/en active Active
- 2018-10-12 ZA ZA2018/06793A patent/ZA201806793B/en unknown
-
2019
- 2019-01-25 JP JP2019011079A patent/JP6877470B2/ja active Active
- 2019-01-25 JP JP2019011084A patent/JP6877472B2/ja active Active
- 2019-01-25 JP JP2019011082A patent/JP6877471B2/ja active Active
- 2019-02-11 HR HRP20190270TT patent/HRP20190270T1/hr unknown
- 2019-03-15 CY CY20191100308T patent/CY1121653T1/el unknown
- 2019-10-02 US US16/591,184 patent/US11364288B2/en active Active
-
2020
- 2020-05-15 AU AU2020203183A patent/AU2020203183B2/en active Active
- 2020-07-19 IL IL276153A patent/IL276153B/en unknown
-
2021
- 2021-03-02 JP JP2021032716A patent/JP2021088599A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02865B (me) | C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae) | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| MX2019005687A (es) | Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas. | |
| IN2014KN01713A (cg-RX-API-DMAC7.html) | ||
| IN2014KN01714A (cg-RX-API-DMAC7.html) | ||
| MX360211B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| HRP20191385T1 (hr) | Povećavanje doze terapije zamjene enzima za liječenje deficijencije kisele sfingomijelinaze | |
| EA201792541A3 (ru) | Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени | |
| EA202090053A3 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| SI2751279T1 (en) | Procedures and compositions for detecting the level of activity of lysosomal exocytosis and application procedures | |
| BRPI0817396C1 (pt) | composição farmacêutica para tratar deficiência de vitamina b¹² | |
| BR112013020042A2 (pt) | inibidores de vírus da hepatite c | |
| WO2015183963A3 (en) | Therapeutic compositions including redox-active parabenzoquinones and uses thereof | |
| RU2011140057A (ru) | Способ профилактики и лечения повышенной проницаемости | |
| MX2017010763A (es) | Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo. | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| WO2019045248A3 (ko) | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 | |
| BR112017010238A2 (pt) | composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação de fibroblastos e a deposição aberrante de matriz extracelular | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| BR112018070819A2 (pt) | peptídeos e composições farmacêuticas, nutracêuticas ou veterinárias para prevenção e/ou tratamento de queda de cabelo | |
| NZ732301A (en) | Peptide compound, preparation method therefor, and application thereof | |
| PH12017502323B1 (en) | Novel xylanase | |
| MY170991A (en) | Dosing regimens of celgosivir for the treatment of dengue | |
| ATE545424T1 (de) | Zusammensetzungen mit lipoteichonsäure zur verwendung bei der behandlung von pleuraerguss oder pneumothorax | |
| BR112015024423A2 (pt) | polipeptídeo glicosilado com cadeia de açúcar sialilada |